The global proteogenomics market was valued at USD 1.18 billion in 2025. It is estimated at USD 1.33 billion in 2026 and is projected to reach USD 3.96 billion by 2036, at a CAGR of 11.5% during the forecast period 2026-2036. This report provides a detailed assessment of the market, covering drug target discovery, population-scale and cancer proteogenomic programs, mass spectrometry and affinity proteomics technologies, data integration and governance, pricing, consolidation among tools providers, the competitive landscape, and future growth opportunities.
The market includes the tools, reagents, software, and services that researchers use to produce and combine protein and genomic data from the same samples or people. Proteogenomics pairs DNA and RNA sequencing with protein measurement to show how genetic variants, mutations, and gene expression translate into protein levels, protein variants, and post-translational modifications. Products in scope include mass spectrometers and NGS systems, sequencing-readout affinity assays such as proximity extension, aptamer, and NULISA tests, reagents for sample handling, enrichment, and library building, single-cell and spatial platforms, bioinformatics for variant peptide detection and data integration, and analysis services. Genomics products used without a protein component, standalone clinical diagnostic tests, and metabolomics and other non-protein omics products are excluded.
According to the National Cancer Institute, its Clinical Proteomic Tumor Analysis Consortium (CPTAC) has made public a pan-cancer proteogenomic resource of more than 1,000 tumors across 10 cancer types through the NCI Cancer Research Data Commons. According to UK Biobank, its Pharma Proteomics Project, run with 14 biopharmaceutical companies on Thermo Fisher Scientific's Olink Explore platform, is measuring more than 5,400 proteins in up to 600,000 samples, with data releases starting in 2026 and the full dataset due in 2027. Genomics England has also used Illumina Protein Prep to profile more than 7,800 rare disease participants from the 100,000 Genomes Project.
Large proteogenomic studies are expensive, since they need both genomic and protein analysis across very large sample sets, and high-resolution mass spectrometers and high-throughput sequencers require major capital outlay. These costs limit use by smaller institutes, biotechnology firms, and laboratories in emerging economies. Tight academic and government funding is also delaying purchases; Seer reported a 23% fall in its revenue for the second quarter of 2026 and tied it to funding pressure and slower sales cycles. Combining data from different platforms remains technically hard, as mass spectrometry and affinity methods differ in protein coverage, sensitivity, and data formats, and few researchers are trained in both proteomics and genomics. Smaller technology providers face financial strain as large tools companies expand.
AI-based integration of genetic, protein, and clinical data is a significant opportunity, with Illumina linking protein data to its DRAGEN software and Illumina Connected Multiomics and launching the Billion Cell Atlas with AstraZeneca, Merck, and Eli Lilly as first partners. Neoantigen discovery for cancer vaccines and T-cell therapies, genomic medicine initiatives across Asia-Pacific and the Middle East, and single-cell and spatial methods that read protein and RNA in the same cells offer further openings. Key trends include consolidation of proteomics and genomics within large tools companies, the growth of population-scale protein datasets, and the combined use of mass spectrometry and affinity proteomics.
By offering, the proteogenomics market is segmented into instruments, consumables & reagents, software & bioinformatics, and services. Consumables & reagents are expected to hold the largest share in 2026, as affinity assays, enrichment and sample preparation reagents, and sequencing reagents are used up in every study, very large projects such as the UK Biobank Pharma Proteomics Project consume them at high volume. Software & bioinformatics is set to record the highest CAGR, because datasets are growing rapidly in size and complexity, researchers must merge protein, genetic, and clinical records, and AI-enabled platforms such as Illumina Connected Multiomics are seeing wider use. Instruments remain an important segment, supported by the new mass spectrometry systems released in 2026, while services gain as drug developers and biobanks outsource large studies.
By technology, the proteogenomics market is segmented into mass spectrometry-based proteogenomics, NGS-based affinity proteogenomics, and single-cell & spatial proteogenomics. In 2026, mass spectrometry-based proteogenomics is expected to lead, given its long use in cancer programs such as CPTAC, its ability to detect protein variants and post-translational modifications, and a steady flow of new high-resolution instruments, including the Orbitrap Tribrid Apex and Orbitrap Excedion introduced in June 2026. NGS-based affinity proteogenomics is set to grow the fastest, as it scales well for population cohorts, Illumina's purchase of SomaLogic brings aptamer assays into the sequencing ecosystem, and Olink was selected for the UK Biobank project; Alamar Biosciences reported 82% revenue growth for its NULISA platform in the second quarter of 2026.
By application, the proteogenomics market is segmented into cancer research & precision oncology, drug target discovery & validation, biomarker discovery, population health & biobank studies, rare & genetic disease research, immunology & infectious disease research, and other applications. Cancer research & precision oncology is expected to hold the largest share in 2026, as proteogenomics is widely used to study tumor biology, find therapeutic targets and neoantigens, and develop biomarkers, backed by open resources such as the CPTAC pan-cancer dataset. Population health & biobank studies are set to grow at the highest CAGR, driven by the UK Biobank Pharma Proteomics Project, Genomics England, and Singapore's PRECISE-SG100K study, which add protein data to large genotyped cohorts and create reference datasets for further research. Drug target discovery & validation is also expected to grow strongly as pharmaceutical companies use pQTL analysis to rank targets.
By end user, the proteogenomics market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, contract research organizations, biobanks & population health programs, and hospitals & clinical research centers. Academic & research institutes are expected to account for the largest share in 2026, since universities, institutes, and publicly funded consortia like CPTAC carry out much of the field's work. Pharmaceutical & biotechnology companies are set to record the highest CAGR, driven by proteogenomic target discovery, biomarker development, and clinical trial analysis, as shown by industry participation in the UK Biobank project and the Illumina Billion Cell Atlas.
In 2026, North America is expected to hold the largest share of the global proteogenomics market, owing to strong research funding, programs such as CPTAC at the National Cancer Institute, a dense base of pharmaceutical and biotechnology companies, and the presence of Thermo Fisher Scientific, Illumina, Alamar Biosciences, and Seer. Open access to CPTAC data supports wide research use in the U.S., although pressure on academic and government budgets may slow parts of the research sector. Canada contributes through academic research and genomics infrastructure. Europe holds a significant share, with the U.K. as the largest country market owing to the UK Biobank and Genomics England programs, Germany as a center for Bruker's proteomics operations, Sweden as the original home of Olink, and Switzerland as the base of Biognosys, while France, the Netherlands, and Denmark also contribute.
Asia-Pacific is projected to grow at the highest CAGR during the forecast period. Singapore's PRECISE-SG100K study is producing protein data alongside genomes with Thermo Fisher Scientific's Orbitrap Astral system under a collaboration with Precision Health Research, Singapore, and Seer and Nanyang Technological University are presenting early findings at HUPO 2026. China is expected to lead the region, supported by large research spending, a strong genomics services industry, and growing proteomics work, while Japan and South Korea are expected to grow strongly and Australia and India are emerging markets. Latin America and the Middle East & Africa hold smaller shares, with genomics initiatives run by the governments of Saudi Arabia, the UAE, and Qatar and academic research in Brazil and Mexico supporting demand.
A few large tools companies that sell mass spectrometers, sequencers, and affinity assays hold a significant part of the proteogenomics market, alongside specialist proteomics and single-cell developers, bioinformatics firms, and service providers. Suppliers compete on proteome depth, sensitivity, throughput, fit with genomics workflows, data analysis, and support for very large studies. Acquisitions are a key strategy: Thermo Fisher Scientific bought Olink in July 2024, Bruker added PreOmics, Biognosys, and biocrates, Illumina closed its purchase of SomaLogic from Standard BioTools in January 2026, and Waters combined with BD's Biosciences and Diagnostic Solutions businesses in February 2026. Alamar Biosciences completed its initial public offering in April 2026, and Seer has received unsolicited acquisition proposals.
Key companies profiled in the report include Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), Danaher Corporation (SCIEX) (U.S.), Bruker Corporation (U.S.), Waters Corporation (U.S.), Alamar Biosciences, Inc. (U.S.), Seer, Inc. (U.S.), 10x Genomics, Inc. (U.S.), and Novogene Co., Ltd. (China).
The market includes the tools, reagents, software, and services that researchers use to produce and combine protein and genomic data from the same samples or people. Proteogenomics pairs DNA and RNA sequencing with protein measurement to show how genetic variants, mutations, and gene expression translate into protein levels, protein variants, and post-translational modifications. Products in scope include mass spectrometers and NGS systems, sequencing-readout affinity assays such as proximity extension, aptamer, and NULISA tests, reagents for sample handling, enrichment, and library building, single-cell and spatial platforms, bioinformatics for variant peptide detection and data integration, and analysis services. Genomics products used without a protein component, standalone clinical diagnostic tests, and metabolomics and other non-protein omics products are excluded.
According to the National Cancer Institute, its Clinical Proteomic Tumor Analysis Consortium (CPTAC) has made public a pan-cancer proteogenomic resource of more than 1,000 tumors across 10 cancer types through the NCI Cancer Research Data Commons. According to UK Biobank, its Pharma Proteomics Project, run with 14 biopharmaceutical companies on Thermo Fisher Scientific's Olink Explore platform, is measuring more than 5,400 proteins in up to 600,000 samples, with data releases starting in 2026 and the full dataset due in 2027. Genomics England has also used Illumina Protein Prep to profile more than 7,800 rare disease participants from the 100,000 Genomes Project.
Market Dynamics
Drug target discovery is a major driver of the proteogenomics market, because most drugs act on proteins and protein levels often differ from what gene or RNA data predict. Linking genome-wide data with measurements of thousands of proteins lets researchers find protein quantitative trait loci (pQTLs) and test whether a protein change causes disease, which gives drug developers stronger genetic support for target choices; GSK, Johnson & Johnson, and Novartis have run proteomic studies with Illumina Protein Prep. Biobanks and national health programs are adding protein data to existing genomic and health records, cancer researchers use proteogenomics to trace how tumor mutations alter proteins and signaling, and newer mass spectrometers and NGS-based affinity assays now measure proteins at a scale close to that of genomics.Large proteogenomic studies are expensive, since they need both genomic and protein analysis across very large sample sets, and high-resolution mass spectrometers and high-throughput sequencers require major capital outlay. These costs limit use by smaller institutes, biotechnology firms, and laboratories in emerging economies. Tight academic and government funding is also delaying purchases; Seer reported a 23% fall in its revenue for the second quarter of 2026 and tied it to funding pressure and slower sales cycles. Combining data from different platforms remains technically hard, as mass spectrometry and affinity methods differ in protein coverage, sensitivity, and data formats, and few researchers are trained in both proteomics and genomics. Smaller technology providers face financial strain as large tools companies expand.
AI-based integration of genetic, protein, and clinical data is a significant opportunity, with Illumina linking protein data to its DRAGEN software and Illumina Connected Multiomics and launching the Billion Cell Atlas with AstraZeneca, Merck, and Eli Lilly as first partners. Neoantigen discovery for cancer vaccines and T-cell therapies, genomic medicine initiatives across Asia-Pacific and the Middle East, and single-cell and spatial methods that read protein and RNA in the same cells offer further openings. Key trends include consolidation of proteomics and genomics within large tools companies, the growth of population-scale protein datasets, and the combined use of mass spectrometry and affinity proteomics.
Segment Analysis
The report analyzes the market by offering, technology, application, end user, and geography, helping stakeholders identify the most attractive areas for product development, partnering, and investment.By offering, the proteogenomics market is segmented into instruments, consumables & reagents, software & bioinformatics, and services. Consumables & reagents are expected to hold the largest share in 2026, as affinity assays, enrichment and sample preparation reagents, and sequencing reagents are used up in every study, very large projects such as the UK Biobank Pharma Proteomics Project consume them at high volume. Software & bioinformatics is set to record the highest CAGR, because datasets are growing rapidly in size and complexity, researchers must merge protein, genetic, and clinical records, and AI-enabled platforms such as Illumina Connected Multiomics are seeing wider use. Instruments remain an important segment, supported by the new mass spectrometry systems released in 2026, while services gain as drug developers and biobanks outsource large studies.
By technology, the proteogenomics market is segmented into mass spectrometry-based proteogenomics, NGS-based affinity proteogenomics, and single-cell & spatial proteogenomics. In 2026, mass spectrometry-based proteogenomics is expected to lead, given its long use in cancer programs such as CPTAC, its ability to detect protein variants and post-translational modifications, and a steady flow of new high-resolution instruments, including the Orbitrap Tribrid Apex and Orbitrap Excedion introduced in June 2026. NGS-based affinity proteogenomics is set to grow the fastest, as it scales well for population cohorts, Illumina's purchase of SomaLogic brings aptamer assays into the sequencing ecosystem, and Olink was selected for the UK Biobank project; Alamar Biosciences reported 82% revenue growth for its NULISA platform in the second quarter of 2026.
By application, the proteogenomics market is segmented into cancer research & precision oncology, drug target discovery & validation, biomarker discovery, population health & biobank studies, rare & genetic disease research, immunology & infectious disease research, and other applications. Cancer research & precision oncology is expected to hold the largest share in 2026, as proteogenomics is widely used to study tumor biology, find therapeutic targets and neoantigens, and develop biomarkers, backed by open resources such as the CPTAC pan-cancer dataset. Population health & biobank studies are set to grow at the highest CAGR, driven by the UK Biobank Pharma Proteomics Project, Genomics England, and Singapore's PRECISE-SG100K study, which add protein data to large genotyped cohorts and create reference datasets for further research. Drug target discovery & validation is also expected to grow strongly as pharmaceutical companies use pQTL analysis to rank targets.
By end user, the proteogenomics market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, contract research organizations, biobanks & population health programs, and hospitals & clinical research centers. Academic & research institutes are expected to account for the largest share in 2026, since universities, institutes, and publicly funded consortia like CPTAC carry out much of the field's work. Pharmaceutical & biotechnology companies are set to record the highest CAGR, driven by proteogenomic target discovery, biomarker development, and clinical trial analysis, as shown by industry participation in the UK Biobank project and the Illumina Billion Cell Atlas.
Regional Analysis
The report covers North America, Europe, Asia-Pacific, the Middle East & Africa, and Latin America, spanning 20 countries and four rest-of-region groups. The regional analysis of the proteogenomics market considers research funding, population-scale and cancer programs, pharmaceutical activity, the presence of technology providers, and data governance and biobank access rules.In 2026, North America is expected to hold the largest share of the global proteogenomics market, owing to strong research funding, programs such as CPTAC at the National Cancer Institute, a dense base of pharmaceutical and biotechnology companies, and the presence of Thermo Fisher Scientific, Illumina, Alamar Biosciences, and Seer. Open access to CPTAC data supports wide research use in the U.S., although pressure on academic and government budgets may slow parts of the research sector. Canada contributes through academic research and genomics infrastructure. Europe holds a significant share, with the U.K. as the largest country market owing to the UK Biobank and Genomics England programs, Germany as a center for Bruker's proteomics operations, Sweden as the original home of Olink, and Switzerland as the base of Biognosys, while France, the Netherlands, and Denmark also contribute.
Asia-Pacific is projected to grow at the highest CAGR during the forecast period. Singapore's PRECISE-SG100K study is producing protein data alongside genomes with Thermo Fisher Scientific's Orbitrap Astral system under a collaboration with Precision Health Research, Singapore, and Seer and Nanyang Technological University are presenting early findings at HUPO 2026. China is expected to lead the region, supported by large research spending, a strong genomics services industry, and growing proteomics work, while Japan and South Korea are expected to grow strongly and Australia and India are emerging markets. Latin America and the Middle East & Africa hold smaller shares, with genomics initiatives run by the governments of Saudi Arabia, the UAE, and Qatar and academic research in Brazil and Mexico supporting demand.
Competitive Landscape
The report provides a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, the competitive dashboard with market leaders, market differentiators, vanguards, and emerging players, and market share/rank analysis by key player for 2025. Company profiles include business overviews, financial performance, product portfolios, strategic developments, and SWOT analyses.A few large tools companies that sell mass spectrometers, sequencers, and affinity assays hold a significant part of the proteogenomics market, alongside specialist proteomics and single-cell developers, bioinformatics firms, and service providers. Suppliers compete on proteome depth, sensitivity, throughput, fit with genomics workflows, data analysis, and support for very large studies. Acquisitions are a key strategy: Thermo Fisher Scientific bought Olink in July 2024, Bruker added PreOmics, Biognosys, and biocrates, Illumina closed its purchase of SomaLogic from Standard BioTools in January 2026, and Waters combined with BD's Biosciences and Diagnostic Solutions businesses in February 2026. Alamar Biosciences completed its initial public offering in April 2026, and Seer has received unsolicited acquisition proposals.
Key companies profiled in the report include Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), Danaher Corporation (SCIEX) (U.S.), Bruker Corporation (U.S.), Waters Corporation (U.S.), Alamar Biosciences, Inc. (U.S.), Seer, Inc. (U.S.), 10x Genomics, Inc. (U.S.), and Novogene Co., Ltd. (China).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global proteogenomics market.
- Explains how drug target discovery, population-scale studies, and cancer research are creating demand for protein and genomic data.
- Assesses the impact of study costs, research funding pressure, and data integration complexity on adoption.
- Identifies high-growth opportunities across offering, technology, application, end user, and region.
- Tracks NGS-based affinity assays, new mass spectrometry platforms, single-cell multiomics, and AI-based data integration.
- Benchmarks leading companies by technology portfolio, proteome coverage, throughput, partnerships, and acquisitions.
- Supports product planning, partnering, acquisition screening, service expansion, and market entry decisions for tools providers, reagent suppliers, service companies, and investors.
Key Questions Answered
- How big is the global proteogenomics market today, and how will it grow through 2036?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- How are population-scale programs such as UK Biobank, Genomics England, and PRECISE-SG100K changing demand?
- Which offering, technology, application, and end-user segments will grow the fastest?
- How will mass spectrometry and NGS-based affinity proteomics compete and work together in proteogenomic studies?
- What role will AI play in integrating and interpreting multiomic data?
- How are research funding constraints affecting instrument purchases and specialist providers?
- Which regions and countries offer the most attractive business opportunities?
- Who are the leading companies, and how are acquisitions changing the competitive landscape?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Overview
5. Proteogenomics Market, by Offering
6. Proteogenomics Market, by Technology
7. Proteogenomics Market, by Application
8. Proteogenomics Market, by End User
9. Proteogenomics Market, by Geography
10. Competitive Landscape
11. Company Profiles
12. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Danaher Corporation
- Bruker Corporation
- Waters Corporation
- Alamar Biosciences, Inc.
- Seer, Inc.
- 10x Genomics, Inc.
- Novogene Co., Ltd.
